The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine

British Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2002, Pages 519-525

  Yasuda, Sally Usdin ^a   Zannikos, Peter ^a   Young, Andrea E ^a   Fried, Karen M ^a   Wainer, Irving W ^a   Woosley, Raymond L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chlorpheniramine; CYP2D6; Pharmacokinetics; Stereoselectivity

Indexed keywords

CHLORPHENIRAMINE; CYTOCHROME P450 2D6; HISTAMINE H1 RECEPTOR; QUINIDINE; ENZYME INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEREOCHEMISTRY; ANIMAL; BLOOD; GUINEA PIG; IN VITRO STUDY; METABOLISM; RADIOASSAY; STEREOISOMERISM;

ADULT; ANIMAL; CHLORPHENIRAMINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; FEMALE; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS; HUMAN; IN VITRO; MALE; QUINIDINE; RADIOLIGAND ASSAY; RECEPTORS, HISTAMINE H1; STEREOISOMERISM; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS;

EID: 0035999647     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01578.x     Document Type: Article

References (22)

1. Comparative pharmacology of chlorpheniramine (Chlor-Trimeton) and its optical isomers
2. 3H]-mepyramine
3. 3H]mepyramine
4. Metabolism of chlorpheniramine maleate in man
5. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults
6. Intravenous administration of chlorpheniramine to seven subjects
7. Report of committee on therapy
8. 1-receptor occupancy
9. d-Sotalol reduces heart rate in vivo through a β-adrenergic receptor-independent mechanism
10. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man
11. 1-receptor antagonist effects of N-0861
12. Salivary analysis for determination of dextromethorphan metabolic phenotype
13. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility
14. The enantioselective determination of chlorpheniramine and its major metabolites in human plasma using chiral chromatography on a β-cyclodextrin chiral stationery phase and mass spectrometric detection
15. Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine
16. Mass fragmentographic determination of d- and l-chlorpheniramine with aid of the stable isotope technique
17. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver
18. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism
19. Genetically-determined interaction between propafenone and low dose quinidine: Role of active metabolites in modulating net drug effect
20. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias
21. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro
22. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4